Aptevo Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2026-08-26.
Aptevo Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on August 26, 2026. The filing reports $3.47M sold. Its industry group is Pharmaceuticals. It names Jeffrey Lamothe (Executive Officer, Director), Marvin White (Executive Officer, Director), Daphne Taylor (Executive Officer) (SEC Form D, August 26, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to Aptevo Therapeutics Inc.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like Aptevo Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-08-26 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Aptevo Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind Aptevo Therapeutics Inc., from the filings we hold.
Roth Capital Partners, LLC received sales compensation on this raise and on 4 other raises we hold, nearest in date first:
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Aptevo Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Aptevo Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Aptevo Therapeutics Inc. →Get the full cited report on Aptevo Therapeutics Inc.
What the filing shows about Aptevo Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aptevo Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Aptevo Therapeutics Inc.'s address as 2401 4th Ave., Suite 1050, Seattle, WA 98121.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Aptevo Therapeutics Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Aptevo Therapeutics Inc. See pricing
Aptevo Therapeutics Inc. is a registered filer with the SEC (CIK 1671584) and has filed since 2025-04-18. 2 filings are on record, the latest on 2026-08-26.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Aptevo Therapeutics Inc.'s Form D of 2026-08-26 names Jeffrey Lamothe, Marvin White, Daphne Taylor and 5 more as its officers, directors or promoters.
Its new offerings report $5.57M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $3.47M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Jeffrey Lamothe is named as Executive Officer and Director on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
Marvin White is named as Executive Officer and Director on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
Daphne Taylor is named as Executive Officer on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
John Niederhuber is named as Director on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
Daniel Abdun-Nabi is named as Director on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
Grady Grant III is named as Director on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
Zsolt Harsanyi is named as Director on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
Barbara Lopez Kunz is named as Director on the Form D that Aptevo Therapeutics Inc. filed with the SEC on 26 August 2026, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2026-08-26 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Aptevo Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aptevo Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aptevo Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Aptevo Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Aptevo Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (aptevotherapeutics.com).
Each opens in a new tab, filled in for Aptevo Therapeutics Inc.. With no account yet, you sign up free and land on the result.
On these lists: Seattle raises, week of 2026-08-24
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/aptevo-therapeutics-inc-form-d-26000001